Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Retained Earnings (2016 - 2025)

Northwest Biotherapeutics' Retained Earnings history spans 16 years, with the latest figure at -$925000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at -$925000.0 for Q4 2025, down 130.4% from a year ago — trailing twelve months through Dec 2025 was -$925000.0 (down 130.4% YoY), and the annual figure for FY2025 was -$925000.0, down 130.4%.
  • Retained Earnings for Q4 2025 was -$925000.0 at Northwest Biotherapeutics, up from -$1.2 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $6.3 million in Q3 2022 to a low of -$1.5 billion in Q2 2025.
  • The 5-year median for Retained Earnings is -$3.1 million (2023), against an average of -$603.0 million.
  • The sharpest move saw Retained Earnings surged 16513.16% in 2022, then plummeted 37450.9% in 2023.
  • Year by year, Retained Earnings stood at -$1.2 billion in 2021, then surged by 100.26% to $3.1 million in 2022, then plummeted by 51.16% to $1.5 million in 2023, then surged by 98.11% to $3.0 million in 2024, then crashed by 130.4% to -$925000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$925000.0, -$1.2 million, and -$1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.